Table 1.
Baseline characteristics (N = 49).
| Characteristic | Patients |
|---|---|
| Age, years | 49 (39–60) |
| Sex | |
| Female | 32 (65) |
| Male | 17 (35) |
| ECOG performance status | |
| 0 | 15 (31) |
| 1 | 33 (67) |
| 2 | 1 (2) |
| Histologic subtype | |
| Liposarcoma | 17 (35) |
| WDLS | 4 (8) |
| DDLS | 11 (22) |
| Myxoid liposarcoma | 2 (4) |
| Leiomyosarcoma | 15 (31) |
| Synovial sarcoma | 4 (8) |
| Fibrosarcoma | 3 (6) |
| Unclassified sarcoma | 3 (6) |
| Angiosarcoma | 1 (2) |
| Undifferentiated pleomorphic sarcoma | 1 (2) |
| Low-grade myofibroblastic sarcoma | 1 (2) |
| Sclerosing epithelioid fibrosarcoma | 1 (2) |
| Epithelioid sarcoma | 1 (2) |
| Epithelioid haemangioendothelioma | 1 (2) |
| Extraskeletal myxoid chondrosarcoma | 1 (2) |
| Primary site | |
| Head and neck | 3 (6) |
| Trunk | 9 (18) |
| Extremities | 7 (14) |
| Retroperitoneum/Intra-abdominal | 22 (45) |
| Viscera | 8 (16) |
| Metastatic site | |
| Lung | 25 (51) |
| Liver | 10 (20) |
| Bone | 5 (10) |
| Lymph node | 2 (4) |
| Othersa | 18 (37) |
| Number of metastatic sites | |
| 0 | 6 (12) |
| 1 | 25 (51) |
| 2 | 9 (18) |
| ≥3 | 9 (18) |
| First-line chemotherapy regimen | |
| MAIDb | 21 (43) |
| AIc | 24 (49) |
| CAV/IEd | 1 (2) |
| Otherse | 3 (6) |
| Cycles of first-line chemotherapy | 5 (4–6) |
| 4 | 24 (49) |
| 5 | 5 (10) |
| 6 | 15 (31) |
| 7 | 1 (2) |
| 8 | 4 (8) |
| Best response to first-line chemotherapy | |
| PR | 9 (18) |
| SD | 40 (82) |
| Previous radiotherapy | |
| Yes | 3 (6) |
| No | 46 (94) |
Data are median (IQR) or n (%).
ECOG = Eastern Cooperative Oncology Group. WDLS = well-differentiated liposarcoma. DDLS = dedifferentiated liposarcoma. PR = partial response. SD = stable disease.
Others refer to metastasis on peritoneum, abdomen or pelvic cavity, pancreas, spleen, kidney, gall bladder, inferior vena cava, extremities and muscles.
MAID refers to combined chemotherapy regimen of mesna, doxorubicin, ifosfamide, dacarbazine.
AI refers to combined chemotherapy regimen of doxorubicin and ifosfamide.
CAV/IE refers to an alternating regimen of cyclophosphamide, doxorubicin and vincristine (CAV), and ifosfamide and etoposide (IE).
Others refer to chemotherapy containing doxorubicin followed by AI, pegylated liposomal doxorubicin plus albumin-bound paclitaxel, doxorubicin plus dacarbazine.